Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LYC-55716
DRUG
2 trials
Sponsors
Lycera Corp.
Conditions
Cancer
Non-small Cell Lung Cancer
Phase 1
Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Completed
NCT02929862
Lycera Corp.
Cancer
Start: 2016-12-31
End: 2019-05-31
Updated: 2019-09-25
Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
NCT03396497
Lycera Corp.
Non-small Cell Lung Cancer
Start: 2018-08-03
End: 2019-10-20
Updated: 2019-09-25
Related Papers
RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial
Annals of Oncology
2018-10-01
6 citations
Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial
Annals of Oncology
2018-10-01
Abstract 5566: LYC-55716, a first-in-class RORγ agonist: Rationale and preclinical data to support clinical combinations with established immunotherapies
Cancer Research
2018-07-01
3 citations
Abstract CT132: Safety and dose selection for LYC-55716, a first-in-class RORγ agonist to treat solid tumors: Phase I results from an open-label, multicenter Phase I/IIa trial
Cancer Research
2018-07-01
2 citations
A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer.
Journal of Clinical Oncology
2018-05-20
2 citations
A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.
Journal of Clinical Oncology
2018-05-20
1 citations
Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion.
Journal of Clinical Oncology
2018-02-20
RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation.
Journal of Clinical Oncology
2018-02-10
Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion.
Journal of Clinical Oncology
2018-02-01
5 citations